Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Insmed Incorporated (INSM)
USD109.14
-6.47 (-5.60%)
US NASDAQ NASDAQ 100
Healthcare Biotechnology
Address
700 US Highway 202/206 8807
Bridgewater, NJ, US
Bridgewater, NJ, US
CEO
William H. Lewis
Website
insmed.com
IPO
2000-06-01
CIK 1104506 ISIN US4576693075
Also trades on
London Stock Exchange · 0JAV.L (USD)
NASDAQ Global Select · INSM (USD)
Description
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Celtrix | CTRX | 2000-02-11 | View |
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| NASDAQ 100 | 2025-12-22 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD109.14
-6.47 (-5.60%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
0.77
Float Shares
193.23M
Free Float %
89.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.66% | -0.78% | -25.07% | -20.64% | -40.33% | -33.35% | +71.22% | +519.33% | +338.40% | +982.09% | -29.70% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (35 ratings, all time)
Buy
Price Targets & DCF
Current price
109.14
Low
160.00
+46.6%
Consensus
214.22
+96.3%
Median
213.50
+95.6%
High
269.00
+146.5%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 17 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 4 |
212.00
+94.2%
|
| Last Quarter | 10 |
208.70
+91.2%
|
| Last Year | 39 |
210.44
+92.8%
|
| All Time | 61 |
159.66
+46.3%
|
Quality scores
Altman Z-Score
5.35
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+66.7% ★ Q1'26: +229.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-15.1% Q1'26: +46.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-223.8% Q1'26: -73.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-195.9% Q1'26: -65.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-1,541.0% Q1'26: -348.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+30.2% Q1'26: +19.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.66× Q1'26: -0.96× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 15 Rev. Ana. 11 EPS Ana. |
Dec 2027 15 Rev. Ana. 12 EPS Ana. |
Dec 2028 17 Rev. Ana. 16 EPS Ana. |
Dec 2029 14 Rev. Ana. 14 EPS Ana. |
Dec 2030 8 Rev. Ana. 14 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11.50M
est: 7.68M (+49.8%)
|
—
est: 28.95M (-100.0%)
|
—
est: 37.89M (-100.0%)
|
—
est: 55.62M (-100.0%)
|
9.84M
est: 7.14M (+37.7%)
|
136.47M
est: 135.84M (+0.5%)
|
164.41M
est: 164.47M (0.0%)
|
188.46M
est: 179.85M (+4.8%)
|
245.36M
est: 247.85M (-1.0%)
|
305.21M
est: 328.61M (-7.1%)
|
363.71M
est: 362.46M (+0.3%)
|
606.42M
est: 582.38M (+4.1%)
|
1.70B
1.55B – 1.79B
+191.4% YoY
|
2.76B
2.40B – 2.99B
+62.8% YoY
|
3.83B
3.83B – 3.83B
+38.6% YoY
|
5.13B
4.43B – 6.08B
+34.0% YoY
|
6.45B
5.56B – 7.64B
+25.6% YoY
|
| EBITDA |
-86.09M
est: -86.17M (+0.1%)
|
-115.28M
est: -110.25M (-4.6%)
|
-170.24M
est: -153.32M (-11.0%)
|
-184.10M
est: -158.70M (-16.0%)
|
-295.18M
est: -292.45M (-0.9%)
|
-217.07M
est: -217.87M (+0.4%)
|
-250.37M
est: -211.38M (-18.4%)
|
-383.65M
est: -353.39M (-8.6%)
|
-447.37M
est: -395.60M (-13.1%)
|
-660.18M
est: -328.61M (-100.9%)
|
-818.79M
est: -362.46M (-125.9%)
|
-1.17B
est: -582.38M (-101.2%)
|
-1.70B
-1.79B – -1.55B
-191.4% YoY
|
-2.76B
-2.99B – -2.40B
-62.8% YoY
|
-3.83B
-3.83B – -3.83B
-38.6% YoY
|
-5.13B
-6.08B – -4.43B
-34.0% YoY
|
-6.45B
-7.64B – -5.56B
-25.6% YoY
|
| EBIT |
-87.17M
est: -87.29M (+0.1%)
|
-117.27M
est: -112.14M (-4.6%)
|
-172.68M
est: -155.56M (-11.0%)
|
-187.00M
est: -161.26M (-16.0%)
|
-300.00M
est: -300.46M (+0.2%)
|
-227.25M
est: -236.47M (+3.9%)
|
-264.52M
est: -224.87M (-17.6%)
|
-397.83M
est: -346.04M (-15.0%)
|
-457.70M
est: -415.66M (-10.1%)
|
-670.76M
est: -328.61M (-104.1%)
|
-829.81M
est: -362.46M (-128.9%)
|
-1.19B
est: -582.38M (-104.0%)
|
-1.70B
-1.79B – -1.55B
-191.4% YoY
|
-2.76B
-2.99B – -2.40B
-62.8% YoY
|
-3.83B
-3.83B – -3.83B
-38.6% YoY
|
-5.13B
-6.08B – -4.43B
-34.0% YoY
|
-6.45B
-7.64B – -5.56B
-25.6% YoY
|
| Net Income |
-79.16M
est: -76.47M (-3.5%)
|
-118.18M
est: -112.79M (-4.8%)
|
-176.27M
est: -158.09M (-11.5%)
|
-192.65M
est: -164.81M (-16.9%)
|
-324.28M
est: -317.40M (-2.2%)
|
-254.34M
est: -255.60M (+0.5%)
|
-294.09M
est: -250.25M (-17.5%)
|
-434.65M
est: -400.47M (-8.5%)
|
-481.53M
est: -434.01M (-11.0%)
|
-749.57M
est: -1.20B (+37.4%)
|
-913.77M
est: -1.15B (+20.8%)
|
-1.28B
est: -1.18B (-7.9%)
|
-582.01M
-1.02B – -303.35M
+50.8% YoY
|
158.41M
-49.94M – 219.40M
+127.2% YoY
|
830.75M
117.08M – 1.39B
+424.4% YoY
|
1.66B
1.36B – 2.05B
+99.4% YoY
|
2.31B
1.90B – 2.87B
+39.5% YoY
|
| SGA |
31.07M
est: 9.15M (+239.5%)
|
43.22M
est: 34.52M (+25.2%)
|
50.68M
est: 45.17M (+12.2%)
|
79.17M
est: 66.31M (+19.4%)
|
168.22M
est: 8.52M (+1,875.4%)
|
210.80M
est: 161.96M (+30.2%)
|
203.61M
est: 196.09M (+3.8%)
|
234.27M
est: 214.43M (+9.3%)
|
265.78M
est: 295.50M (-10.1%)
|
344.50M
est: 386.38M (-10.8%)
|
461.12M
est: 426.19M (+8.2%)
|
701.17M
est: 684.77M (+2.4%)
|
2.00B
1.82B – 2.10B
+191.4% YoY
|
3.25B
2.82B – 3.51B
+62.8% YoY
|
4.50B
4.50B – 4.50B
+38.6% YoY
|
6.03B
5.20B – 7.15B
+34.0% YoY
|
7.58B
6.54B – 8.98B
+25.6% YoY
|
| EPS |
-1.84
est: -1.93 (+4.7%)
|
-2.02
est: -1.99 (-1.7%)
|
-2.85
est: -2.65 (-7.6%)
|
-2.89
est: -2.62 (-10.4%)
|
-4.22
est: -4.02 (-4.9%)
|
-3.01
est: -2.96 (-1.8%)
|
-3.01
est: -2.60 (-15.6%)
|
-3.88
est: -3.82 (-1.6%)
|
-3.91
est: -3.72 (-5.2%)
|
-5.34
est: -5.43 (+1.7%)
|
-5.57
est: -5.36 (-3.8%)
|
-6.41
est: -5.85 (-9.5%)
|
-2.78
-4.79 – -1.42
+52.5% YoY
|
0.53
-0.23 – 1.03
+119.1% YoY
|
3.57
0.55 – 6.51
+569.8% YoY
|
7.75
6.37 – 9.61
+117.3% YoY
|
10.82
8.89 – 13.42
+39.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-17 | Roth Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-784.27M
OE per share TTM
-3.79
Owner's Yield
-3.47%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
38.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
170
Total invested
867.13M
Insider transactions (90d)
2
Beneficial owners (>5%)
20
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group - 23-1945930 | 11.12M | 9.39% | — | 223.6K | 10.79M | 328.5K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 2 | Darwin Global Management, Ltd. | 9.72M | 5.70% | — | 9.72M | — | — | IA, OO | Jersey | 2024-09-03 | ↗ |
| 3 | Dr. Abhishek Trehan | 9.72M | 5.70% | — | 9.72M | — | — | IN | United Kingdom | 2024-09-03 | ↗ |
| 4 | (1) BlackRock, Inc. | 9.32M | 7.90% | 9.21M | — | 9.32M | — | HC | Delaware | 2022-02-08 | ↗ |
| 5 | Darwin Global Master Fund, Ltd. | 9.31M | 5.40% | — | 9.31M | — | — | OO | Cayman Islands | 2024-09-03 | ↗ |
| 6 | 52-0556948 | 9.25M | 7.70% | 1.77M | — | 9.25M | — | IA | Maryland | 2022-08-10 | ↗ |
| 7 | Janus Henderson Group plc | 7.88M | 6.70% | — | 7.88M | — | 7.88M | IA, HC | Jersey, Channel Islands | 2022-02-10 | ↗ |
| 8 | STATE STREET CORPORATION | 6.89M | 5.08% | — | 6.60M | — | 6.89M | HC | BOSTON, MASSACHUSETTS | 2023-02-03 | ↗ |
| 9 | Anthony Joonkyoo Yun, MD | 6.03M | 5.09% | — | — | — | 6.03M | HC, IN | USA | 2022-02-14 | ↗ |
| 10 | PAI LLC | 6.03M | 5.09% | — | — | — | 6.03M | IA, OO | California | 2022-02-14 | ↗ |
| 11 | Palo Alto Investors LP | 6.03M | 5.09% | — | — | — | 6.03M | IA, OO | California | 2022-02-14 | ↗ |
| 12 | Patrick Lee, MD | 6.03M | 5.09% | — | — | — | 6.03M | HC, IN | USA | 2022-02-14 | ↗ |
| 13 | Abigail P. Johnson | 5.97M | 5.79% | — | — | 5.97M | — | IN | Delaware | 2021-04-12 | ↗ |
| 14 | FMR LLC | 5.97M | 5.79% | 210.0K | — | 5.97M | — | HC | Delaware | 2021-04-12 | ↗ |
| 15 | 85-4328500 | 5.85M | 4.10% | 8.91M | — | 33.23M | — | IA | Maryland | 2024-02-14 | ↗ |
| 16 | Palo Alto Healthcare Master Fund II, L.P. | 4.33M | 5.62% | — | 4.33M | — | 4.33M | PN | Cayman Islands | 2019-02-14 | ↗ |
| 17 | OrbiMed Advisors LLC | 859.7K | 1.12% | — | 859.7K | — | — | IA | Delaware | 2018-02-13 | ↗ |
| 18 | OrbiMed Capital LLC | 637.1K | 0.83% | — | 637.1K | — | — | IA | Delaware | 2018-02-13 | ↗ |
| 19 | Point72 Asset Management, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 20 | Point72 Capital Advisors, Inc. | — | 0.00% | — | — | — | — | CO | Delaware | 2016-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
170
-552 vs prev Q
New positions
18
Closed positions
527
Increased
83
Reduced
58
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 1.18M +1.2M (+100.0%) | 205.89B +205.9B (+100.0%) | 0.56% +0.559 pp | 0.31% +0.311 pp | USD174.04 +0.0% | 1 qtrs NEW |
| 2 | JPMORGAN CHASE & CO | 23.20M +151.8K (+0.7%) | 4.04B +718.5M (+21.6%) | 10.96% -1.220 pp | 0.25% +0.055 pp | USD106.44 +63.5% | 51 qtrs — |
| 3 | VANGUARD GROUP INC | 21.08M +1.1M (+5.7%) | 3.67B +797.2M (+27.8%) | 9.95% +0.539 pp | 0.05% +0.010 pp | USD52.53 +231.3% | 60 qtrs — |
| 4 | DARWIN GLOBAL MANAGEMENT, LTD. | 20.93M +475.8K (+2.3%) | 3.64B +746.5M (+25.8%) | 9.89% +0.225 pp | 73.78% -6.763 pp | USD83.07 +109.5% | 7 qtrs — |
| 5 | BLACKROCK, INC. | 15.07M +2.7M (+21.8%) | 2.62B +841.3M (+47.2%) | 7.11% +1.275 pp | 0.04% +0.013 pp | USD96.68 +80.0% | 6 qtrs — |
| 6 | FMR LLC | 9.93M +747.0K (+8.1%) | 1.73B +405.7M (+30.7%) | 4.69% +0.353 pp | 0.09% +0.019 pp | USD97.68 +78.2% | 58 qtrs — |
| 7 | BAKER BROS. ADVISORS LP | 6.59M -110.7K (-1.7%) | 1.15B +182.0M (+18.9%) | 3.11% -0.052 pp | 6.72% -0.258 pp | USD75.94 +129.2% | 53 qtrs — |
| 8 | STATE STREET CORP | 5.20M +1.2M (+30.6%) | 905.31M +331.5M (+57.8%) | 2.46% +0.575 pp | 0.03% +0.011 pp | USD68.08 +155.6% | 51 qtrs — |
| 9 | CAPITAL INTERNATIONAL INVESTORS | 5.15M -2.4M (-31.8%) | 896.60M -191.2M (-17.6%) | 2.43% -1.134 pp | 0.14% -0.035 pp | USD60.78 +186.3% | 8 qtrs — |
| 10 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 4.84M -93.9K (-1.9%) | 843.01M +131.9M (+18.6%) | 2.29% -0.044 pp | 1.26% +0.253 pp | USD93.40 +86.3% | 7 qtrs — |
| 11 | RTW INVESTMENTS, LP | 4.84M +1.8M (+57.0%) | 842.85M +398.6M (+89.7%) | 2.29% +0.830 pp | 8.44% +2.970 pp | USD92.12 +88.9% | 11 qtrs — |
| 12 | D. E. SHAW & CO., INC. | 4.35M -1.3M (-23.1%) | 757.25M -57.5M (-7.1%) | 2.05% -0.617 pp | 0.42% -0.045 pp | USD113.66 +53.1% | 60 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 4.30M +539.6K (+14.4%) | 751.94M +210.4M (+38.9%) | 2.03% +0.255 pp | 0.05% +0.012 pp | USD63.54 +173.9% | 60 qtrs — |
| 14 | ORBIS ALLAN GRAY LTD | 4.18M +929.1K (+28.6%) | 727.48M +259.3M (+55.4%) | 1.97% +0.439 pp | 3.05% +1.039 pp | USD134.87 +29.0% | 3 qtrs — |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.04M -2.9M (-41.7%) | 703.03M -295.2M (-29.6%) | 1.91% -1.366 pp | 0.08% -0.031 pp | USD32.63 +433.4% | 48 qtrs — |
| 16 | NORGES BANK | 2.91M +2.9M (+100.0%) | 506.63M +506.6M (+100.0%) | 1.37% +1.375 pp | 0.05% +0.054 pp | USD174.04 +0.0% | 1 qtrs NEW |
| 17 | FRANKLIN RESOURCES INC | 2.76M +615.8K (+28.8%) | 479.57M +171.4M (+55.6%) | 1.30% +0.291 pp | 0.12% +0.041 pp | USD61.80 +181.6% | 27 qtrs — |
| 18 | INVESCO LTD. | 2.73M +723.0K (+36.1%) | 474.58M +186.0M (+64.5%) | 1.29% +0.341 pp | 0.07% +0.027 pp | USD100.53 +73.1% | 37 qtrs — |
| 19 | AMERIPRISE FINANCIAL INC | 1.97M -753.0K (-27.7%) | 342.66M -49.3M (-12.6%) | 0.93% -0.356 pp | 0.08% -0.013 pp | USD32.84 +430.0% | 51 qtrs — |
| 20 | UBS GROUP AG | 1.87M +221.4K (+13.4%) | 325.04M +88.0M (+37.1%) | 0.88% +0.105 pp | 0.05% +0.016 pp | USD132.81 +31.0% | 45 qtrs — |
| 21 | BANK OF AMERICA CORP /DE/ | 1.73M +123.9K (+7.7%) | 300.34M +69.7M (+30.2%) | 0.81% -0.031 pp | 0.02% +0.006 pp | USD71.03 +145.0% | 52 qtrs — |
| 22 | MORGAN STANLEY | 1.63M +668.3K (+69.3%) | 284.02M +145.2M (+104.7%) | 0.77% +0.316 pp | 0.02% +0.009 pp | USD98.08 +77.4% | 51 qtrs — |
| 23 | DUQUESNE FAMILY OFFICE LLC | 1.48M -941.7K (-38.9%) | 257.88M -91.1M (-26.1%) | 0.70% -0.445 pp | 5.74% -2.854 pp | USD88.13 +97.5% | 7 qtrs — |
| 24 | BANK OF NEW YORK MELLON CORP | 1.39M +251.1K (+22.1%) | 241.92M +77.9M (+47.5%) | 0.66% +0.119 pp | 0.04% +0.011 pp | USD49.61 +250.8% | 59 qtrs — |
| 25 | MILLENNIUM MANAGEMENT LLC | 1.31M -1.0M (-43.9%) | 228.28M -108.1M (-32.1%) | 0.62% -0.484 pp | 0.10% -0.048 pp | USD92.55 +88.0% | 25 qtrs — |
| 26 | CASTLE HOOK PARTNERS LP | 1.25M +162.2K (+14.9%) | 218.17M +61.0M (+38.8%) | 0.59% +0.077 pp | 0.91% +0.110 pp | USD132.23 +31.6% | 3 qtrs — |
| 27 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.25M -350.0K (-21.9%) | 217.55M -12.9M (-5.6%) | 0.59% -0.165 pp | 10.80% -4.787 pp | USD38.34 +353.9% | 9 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 1.24M +415.6K (+50.1%) | 216.66M +97.2M (+81.4%) | 0.59% +0.196 pp | 0.03% +0.012 pp | USD98.33 +77.0% | 60 qtrs — |
| 29 | NORTHERN TRUST CORP | 1.24M +165.5K (+15.4%) | 215.54M +61.0M (+39.5%) | 0.58% +0.078 pp | 0.03% +0.008 pp | USD60.22 +189.0% | 51 qtrs — |
| 30 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.22M -334.0K (-21.5%) | 212.52M -11.4M (-5.1%) | 0.58% -0.158 pp | 0.59% +0.014 pp | USD27.35 +536.3% | 24 qtrs — |
| 31 | CITADEL ADVISORS LLC | 1.16M -900.3K (-43.8%) | 201.42M -94.9M (-32.0%) | 0.55% -0.425 pp | 0.03% -0.015 pp | USD99.29 +75.3% | 31 qtrs — |
| 32 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.03M +52.1K (+5.3%) | 178.80M +38.4M (+27.3%) | 0.49% +0.025 pp | 0.03% +0.005 pp | USD44.19 +293.8% | 51 qtrs — |
| 33 | FIERA CAPITAL CORP | 992.9K +183.8K (+22.7%) | 172.80M +56.3M (+48.3%) | 0.47% +0.087 pp | 0.55% +0.171 pp | USD96.88 +79.6% | 7 qtrs — |
| 34 | NWI MANAGEMENT LP | 988.5K -32.5K (-3.2%) | 172.03M +25.0M (+17.0%) | 0.47% -0.073 pp | 7.92% +0.082 pp | USD101.09 +72.2% | 6 qtrs — |
| 35 | TWO SIGMA INVESTMENTS, LP | 962.2K +189.4K (+24.5%) | 167.45M +56.2M (+50.5%) | 0.45% +0.089 pp | 0.24% +0.071 pp | USD119.50 +45.6% | 35 qtrs — |
| 36 | PICTET ASSET MANAGEMENT HOLDING SA | 959.0K -181.9K (-15.9%) | 167.26M +3.3M (+2.0%) | 0.45% -0.086 pp | 0.16% +0.004 pp | USD37.53 +363.7% | 10 qtrs — |
| 37 | UBS ASSET MANAGEMENT AMERICAS INC | 943.3K +430.6K (+84.0%) | 164.17M +90.3M (+122.3%) | 0.45% +0.203 pp | 0.03% +0.019 pp | USD107.41 +62.0% | 35 qtrs — |
| 38 | JEFFERIES FINANCIAL GROUP INC. | 926.3K +818.2K (+757.0%) | 161.22M +145.7M (+935.6%) | 0.44% +0.386 pp | 0.82% +0.750 pp | USD170.21 +2.3% | 13 qtrs — |
| 39 | AMUNDI | 917.0K +599.9K (+189.2%) | 159.59M +109.4M (+218.0%) | 0.43% +0.283 pp | 0.04% +0.027 pp | USD163.11 +6.7% | 5 qtrs — |
| 40 | BNP PARIBAS ARBITRAGE, SNC | 915.4K +482.1K (+111.2%) | 159.32M +96.9M (+155.3%) | 0.43% +0.228 pp | 0.07% +0.039 pp | USD130.77 +33.1% | 51 qtrs — |
| 41 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 909.1K -132.8K (-12.7%) | 158.22M +8.2M (+5.5%) | 0.43% -0.063 pp | 3.29% +0.177 pp | USD81.56 +113.4% | 9 qtrs — |
| 42 | SEI INVESTMENTS CO | 890.2K +296.3K (+49.9%) | 154.92M +69.4M (+81.1%) | 0.42% +0.140 pp | 0.15% +0.061 pp | USD114.94 +51.4% | 34 qtrs — |
| 43 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 849.6K +1.2K (+0.1%) | 147.86M +25.7M (+21.0%) | 0.40% +0.001 pp | 0.02% +0.003 pp | USD87.88 +98.0% | 17 qtrs — |
| 44 | FIL LTD | 838.5K -13.4K (-1.6%) | 145.93M +23.2M (+18.9%) | 0.40% -0.006 pp | 0.11% +0.013 pp | USD56.97 +205.5% | 14 qtrs — |
| 45 | CLEARBRIDGE INVESTMENTS, LLC | 819.0K -249.0K (-23.3%) | 142.54M -11.3M (-7.3%) | 0.39% -0.118 pp | 0.11% -0.002 pp | USD47.40 +267.2% | 8 qtrs — |
| 46 | HOLOCENE ADVISORS, LP | 801.2K -282.5K (-26.1%) | 139.43M -16.6M (-10.7%) | 0.38% -0.133 pp | 0.29% -0.063 pp | USD73.83 +135.7% | 5 qtrs — |
| 47 | JANUS HENDERSON GROUP PLC | 800.6K -402.2K (-33.4%) | 139.33M -33.9M (-19.6%) | 0.38% -0.190 pp | 0.06% -0.017 pp | USD52.04 +234.4% | 35 qtrs — |
| 48 | RAYMOND JAMES FINANCIAL INC | 779.3K +19.3K (+2.5%) | 135.65M +26.2M (+23.9%) | 0.37% +0.009 pp | 0.04% +0.007 pp | USD86.80 +100.5% | 5 qtrs — |
| 49 | PRINCIPAL FINANCIAL GROUP INC | 771.4K -92.9K (-10.8%) | 134.25M +9.8M (+7.9%) | 0.36% -0.044 pp | 0.07% +0.006 pp | USD34.27 +407.8% | 51 qtrs — |
| 50 | LORD, ABBETT & CO. LLC | 720.9K -723.8K (-50.1%) | 125.47M -82.6M (-39.7%) | 0.34% -0.342 pp | 0.38% -0.235 pp | USD74.19 +134.6% | 7 qtrs — |
| 51 | ARTIA GLOBAL PARTNERS LP | 682.2K -50.0K (-6.8%) | 118.73M +13.3M (+12.6%) | 0.32% -0.024 pp | 18.93% +2.242 pp | USD85.94 +102.5% | 9 qtrs — |
| 52 | NUVEEN, LLC | 650.4K +62.3K (+10.6%) | 113.20M +28.5M (+33.7%) | 0.31% +0.029 pp | 0.03% +0.007 pp | USD85.65 +103.2% | 4 qtrs — |
| 53 | VICTORY CAPITAL MANAGEMENT INC | 646.7K +291.8K (+82.2%) | 112.55M +61.4M (+120.2%) | 0.31% +0.138 pp | 0.06% +0.034 pp | USD136.38 +27.6% | 26 qtrs — |
| 54 | ALLIANCEBERNSTEIN L.P. | 642.7K -226.1K (-26.0%) | 111.86M -13.3M (-10.6%) | 0.30% -0.107 pp | 0.04% -0.004 pp | USD33.86 +414.0% | 52 qtrs — |
| 55 | HOOD RIVER CAPITAL MANAGEMENT LLC | 637.6K -243.8K (-27.7%) | 110.96M -16.0M (-12.6%) | 0.30% -0.115 pp | 1.22% -0.282 pp | USD45.32 +284.0% | 9 qtrs — |
| 56 | FEDERATED HERMES, INC. | 632.3K +304.1K (+92.6%) | 110.05M +62.8M (+132.8%) | 0.30% +0.144 pp | 0.18% +0.100 pp | USD145.67 +19.5% | 10 qtrs — |
| 57 | DEUTSCHE BANK AG\ | 590.0K +385.7K (+188.7%) | 102.69M +73.3M (+248.9%) | 0.28% +0.182 pp | 0.03% +0.024 pp | USD130.03 +33.8% | 50 qtrs — |
| 58 | WELLS FARGO & COMPANY/MN | 586.7K +72.8K (+14.2%) | 102.10M +28.1M (+38.0%) | 0.28% +0.034 pp | 0.02% +0.005 pp | USD113.99 +52.7% | 49 qtrs — |
| 59 | SWISS NATIONAL BANK | 579.1K +207.8K (+56.0%) | 100.79M +47.3M (+88.5%) | 0.27% +0.098 pp | 0.06% +0.029 pp | USD89.68 +94.1% | 49 qtrs — |
| 60 | SUSQUEHANNA ADVISORS GROUP, INC. | 565.0K +565.0K (+100.0%) | 98.33M +98.3M (+100.0%) | 0.27% +0.267 pp | 1.63% +1.633 pp | USD174.04 +0.0% | 1 qtrs NEW |
| 61 | JENNISON ASSOCIATES LLC | 562.3K -40.5K (-6.7%) | 97.86M +11.1M (+12.7%) | 0.27% -0.019 pp | 0.06% +0.008 pp | USD61.16 +184.6% | 9 qtrs — |
| 62 | LEGAL & GENERAL GROUP PLC | 540.3K +332.3K (+159.7%) | 94.04M +64.1M (+213.9%) | 0.26% +0.157 pp | 0.02% +0.014 pp | USD123.67 +40.7% | 46 qtrs — |
| 63 | ROYAL BANK OF CANADA | 506.8K -848.5K (-62.6%) | 88.21M -107.0M (-54.8%) | 0.24% -0.401 pp | 0.01% -0.018 pp | USD123.59 +40.8% | 47 qtrs — |
| 64 | NEARWATER CAPITAL MARKETS, LTD | 500.0K +300.0K (+150.0%) | 87.02M +58.2M (+202.1%) | 0.24% +0.142 pp | 1.49% +1.103 pp | USD162.03 +7.4% | 2 qtrs — |
| 65 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 490.5K +65.4K (+15.4%) | 85.37M +24.2M (+39.5%) | 0.23% +0.031 pp | 1.29% +0.411 pp | USD86.85 +100.4% | 6 qtrs — |
| 66 | PALO ALTO INVESTORS LP | 489.5K -2.3K (-0.5%) | 85.19M +14.4M (+20.3%) | 0.23% -0.001 pp | 11.86% -1.247 pp | USD17.74 +881.1% | 60 qtrs — |
| 67 | WELLINGTON MANAGEMENT GROUP LLP | 486.1K -231.9K (-32.3%) | 84.61M -18.8M (-18.2%) | 0.23% -0.110 pp | 0.01% -0.003 pp | USD70.27 +147.7% | 7 qtrs — |
| 68 | EVENTIDE ASSET MANAGEMENT, LLC | 483.6K -521.5K (-51.9%) | 84.16M -60.6M (-41.8%) | 0.23% -0.246 pp | 1.31% -1.065 pp | USD44.19 +293.8% | 13 qtrs — |
| 69 | GW&K INVESTMENT MANAGEMENT, LLC | 482.7K -119.1K (-19.8%) | 84.01M -2.7M (-3.1%) | 0.23% -0.056 pp | 0.73% -0.040 pp | USD45.45 +282.9% | 21 qtrs — |
| 70 | AQR CAPITAL MANAGEMENT LLC | 468.3K +181.0K (+63.0%) | 81.50M +40.6M (+99.1%) | 0.22% +0.086 pp | 0.04% +0.017 pp | USD144.99 +20.0% | 43 qtrs — |
| 71 | JANE STREET GROUP, LLC | 463.6K -318.8K (-40.7%) | 80.68M -32.0M (-28.4%) | 0.22% -0.151 pp | 0.01% -0.005 pp | USD77.08 +125.8% | 6 qtrs — |
| 72 | AFFINITY ASSET ADVISORS, LLC | 450.0K +— (+0.0%) | 78.32M +13.5M (+20.9%) | 0.21% +0.000 pp | 4.46% -1.183 pp | USD92.42 +88.3% | 7 qtrs — |
| 73 | BARCLAYS PLC | 444.7K +112.6K (+33.9%) | 77.40M +53.2M (+219.3%) | 0.21% +0.035 pp | 0.02% +0.012 pp | USD115.16 +51.1% | 51 qtrs — |
| 74 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 435.4K +435.4K (+100.0%) | 75.78M +75.8M (+100.0%) | 0.21% +0.206 pp | 0.04% +0.045 pp | USD174.04 +0.0% | 1 qtrs NEW |
| 75 | WESTFIELD CAPITAL MANAGEMENT CO LP | 432.5K -55.4K (-11.4%) | 75.28M +5.0M (+7.1%) | 0.20% -0.026 pp | 0.31% +0.019 pp | USD72.16 +141.2% | 6 qtrs — |
| 76 | CANDRIAM S.C.A. | 401.0K +3.5K (+0.9%) | 69.80M +12.5M (+21.9%) | 0.19% +0.002 pp | 0.35% +0.048 pp | USD38.80 +348.6% | 23 qtrs — |
| 77 | DIMENSIONAL FUND ADVISORS LP | 399.1K +12.4K (+3.2%) | 69.46M +13.8M (+24.8%) | 0.19% +0.006 pp | 0.01% +0.003 pp | USD78.71 +121.1% | 18 qtrs — |
| 78 | TWO SIGMA ADVISERS, LP | 395.0K +343.7K (+670.0%) | 68.75M +61.4M (+830.5%) | 0.19% +0.162 pp | 0.13% +0.119 pp | USD165.33 +5.3% | 34 qtrs — |
| 79 | MARSHALL WACE, LLP | 389.9K -268.8K (-40.8%) | 67.85M -27.0M (-28.5%) | 0.18% -0.127 pp | 0.06% -0.034 pp | USD62.03 +180.6% | 11 qtrs — |
| 80 | ENSIGN PEAK ADVISORS, INC | 382.2K -259.8K (-40.5%) | 66.52M -25.9M (-28.1%) | 0.18% -0.123 pp | 0.12% -0.034 pp | USD57.34 +203.5% | 17 qtrs — |
| 81 | BALYASNY ASSET MANAGEMENT L.P. | 380.6K +343.1K (+915.3%) | 66.23M +60.8M (+1,127.1%) | 0.18% +0.162 pp | 0.08% +0.077 pp | USD171.08 +1.7% | 2 qtrs — |
| 82 | SAMLYN CAPITAL, LLC | 369.6K +76.9K (+26.3%) | 64.32M +22.2M (+52.6%) | 0.17% +0.036 pp | 1.02% +0.445 pp | USD150.26 +15.8% | 2 qtrs — |
| 83 | GATEWAY INVESTMENT ADVISERS LLC | 365.0K +365.0K (+100.0%) | 63.52M +63.5M (+100.0%) | 0.17% +0.172 pp | 0.59% +0.591 pp | USD174.04 +0.0% | 1 qtrs NEW |
| 84 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 354.9K +44.0K (+14.2%) | 61.77M +17.0M (+38.0%) | 0.17% +0.021 pp | 0.04% +0.009 pp | USD81.18 +114.4% | 58 qtrs — |
| 85 | POLAR CAPITAL HOLDINGS PLC | 344.2K -27.7K (-7.4%) | 59.91M +6.4M (+11.9%) | 0.16% -0.013 pp | 0.23% -0.026 pp | USD55.94 +211.1% | 21 qtrs — |
| 86 | PROSHARE ADVISORS LLC | 340.7K +333.2K (+4,425.1%) | 59.30M +58.2M (+5,368.7%) | 0.16% +0.157 pp | 0.10% +0.102 pp | USD171.44 +1.5% | 50 qtrs — |
| 87 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 328.3K +129.6K (+65.2%) | 57.16M +28.5M (+99.7%) | 0.16% +0.061 pp | 0.07% -0.009 pp | USD88.54 +96.6% | 16 qtrs — |
| 88 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 319.3K -65.8K (-17.1%) | 55.56M +118.4K (+0.2%) | 0.15% -0.031 pp | 2.85% -0.390 pp | USD66.93 +160.0% | 7 qtrs — |
| 89 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 310.3K +130.9K (+73.0%) | 54.01M +28.2M (+109.1%) | 0.15% +0.062 pp | 0.05% +0.028 pp | USD94.59 +84.0% | 51 qtrs — |
| 90 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 300.0K -952.5K (-76.0%) | 52.21M -128.2M (-71.1%) | 0.14% -0.450 pp | 0.08% -0.207 pp | USD69.69 +149.7% | 10 qtrs — |
| 91 | FRONTIER CAPITAL MANAGEMENT CO LLC | 284.8K -44.0K (-13.4%) | 49.57M +2.2M (+4.7%) | 0.13% -0.021 pp | 0.53% +0.102 pp | USD96.68 +80.0% | 8 qtrs — |
| 92 | ZURICH INSURANCE GROUP LTD/FI | 281.1K +281.1K (+100.0%) | 48.92M +48.9M (+100.0%) | 0.13% +0.133 pp | 0.34% +0.339 pp | USD174.04 +0.0% | 1 qtrs NEW |
| 93 | NATIONAL PENSION SERVICE | 280.4K +280.4K (+100.0%) | 48.81M +48.8M (+100.0%) | 0.13% +0.132 pp | 0.04% +0.036 pp | USD174.04 +0.0% | 1 qtrs NEW |
| 94 | NEW YORK STATE COMMON RETIREMENT FUND | 276.3K -169.6K (-38.0%) | 48.08M -16.1M (-25.1%) | 0.13% -0.080 pp | 0.06% -0.019 pp | USD71.30 +144.1% | 44 qtrs — |
| 95 | ENVESTNET ASSET MANAGEMENT INC | 276.1K -66.7K (-19.5%) | 48.05M -1.3M (-2.7%) | 0.13% -0.032 pp | 0.01% +0.000 pp | USD66.64 +161.2% | 24 qtrs — |
| 96 | CORMORANT ASSET MANAGEMENT, LP | 275.0K -155.0K (-36.0%) | 47.86M -14.1M (-22.7%) | 0.13% -0.073 pp | 2.21% -2.060 pp | USD41.72 +317.2% | 10 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.30
Bearish
Ratio by volume
0.50
Neutral
Buys
7
Sells
23
Shares acquired
120.2K
Shares disposed
240.3K
Cash buys
—
Cash sales
16.00
Net activity
-120,157
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 4,440 | 17.16 | 76.2K | 311,884 | D | ↗ |
| 2026-04-16 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 5,373 | 143.81 | 772.7K | 304,265 | D | ↗ |
| 2026-04-06 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 8,478 | 163.23 | 1.38M | 302,619 | D | ↗ |
| 2026-04-01 | Adsett Roger | Officer | M-Exempt | A | Common Stock | 88,060 | 14.56 | 1.28M | 194,870 | D | ↗ |
| 2026-03-30 | Smith Michael Alexander | Officer | M-Exempt | D | Stock Option (right to buy) | 13,989 | 27.89 | 390.2K | 18,561 | D | ↗ |
| 2026-03-19 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 4,440 | 17.16 | 76.2K | 311,884 | D | ↗ |
| 2026-03-05 | Lewis William | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 4,440 | 17.16 | 76.2K | 39,960 | D | ↗ |
| 2026-03-03 | SHAROKY MELVIN MD | Director | G-Gift | D | Common Stock | 100 | 0.00 | — | 242,776 | D | ↗ |
| 2026-02-25 | SHAROKY MELVIN MD | Director | G-Gift | A | Common Stock | 243 | 0.00 | — | 5,007 | I | ↗ |
| 2026-02-24 | Smith Michael Alexander | Officer | M-Exempt | A | Common Stock | 20,248 | 17.07 | 345.6K | 76,645 | D | ↗ |
| 2026-02-23 | Brennan David R | Director | G-Gift | D | Common Stock | 6,000 | 0.00 | — | 60,933 | D | ↗ |
| 2026-02-19 | Lewis William | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 6,259 | 30.46 | 190.6K | 62,591 | D | ↗ |
| 2026-02-09 | MCGIRR DAVID W J | Director | G-Gift | A | Common Stock | 53,400 | 0.00 | — | 53,400 | I | ↗ |
| 2026-02-09 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 6,259 | 30.46 | 190.6K | 314,581 | D | ↗ |
| 2026-02-05 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 869 | 152.44 | 132.5K | 83,243 | D | ↗ |
| 2026-02-03 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 640 | 156.27 | 100.0K | 56,397 | D | ↗ |
| 2026-02-03 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 3,009 | 156.34 | 470.4K | 303,882 | D | ↗ |
| 2026-02-03 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 795 | 155.77 | 123.8K | 84,112 | D | ↗ |
| 2026-02-03 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 748 | 156.34 | 116.9K | 79,758 | D | ↗ |
| 2026-02-03 | Adsett Roger | Officer | S-Sale | D | Common Stock | 791 | 156.17 | 123.5K | 106,810 | D | ↗ |
| 2026-02-02 | Flammer Martina M.D. | Officer | M-Exempt | A | Common Stock | 7,982 | 65.72 | 524.6K | 92,889 | D | ↗ |
| 2026-01-20 | Lewis William | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 4,440 | 17.16 | 76.2K | 53,280 | D | ↗ |
| 2026-01-12 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 160 | 170.24 | 27.2K | 307,800 | D | ↗ |
| 2026-01-09 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 1,887 | 186.19 | 351.3K | 84,907 | D | ↗ |
| 2026-01-08 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 1,053 | 174.17 | 183.4K | 57,037 | D | ↗ |
| 2026-01-08 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 3,223 | 174.17 | 561.3K | 315,407 | D | ↗ |
| 2026-01-08 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 1,660 | 173.87 | 288.6K | 90,045 | D | ↗ |
| 2026-01-08 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 1,447 | 174.17 | 252.0K | 80,506 | D | ↗ |
| 2026-01-08 | Adsett Roger | Officer | S-Sale | D | Common Stock | 2,059 | 174.17 | 358.6K | 107,601 | D | ↗ |
| 2026-01-07 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 709 | 175.07 | 124.1K | 58,090 | D | ↗ |
| 2026-01-07 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 2,357 | 175.07 | 412.6K | 318,630 | D | ↗ |
| 2026-01-07 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 1,434 | 175.84 | 252.2K | 91,705 | D | ↗ |
| 2026-01-07 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 1,678 | 175.07 | 293.8K | 81,953 | D | ↗ |
| 2026-01-07 | Adsett Roger | Officer | S-Sale | D | Common Stock | 802 | 175.07 | 140.4K | 109,660 | D | ↗ |
| 2026-01-06 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 1,396 | 173.33 | 242.0K | 58,799 | D | ↗ |
| 2026-01-06 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 4,096 | 173.33 | 710.0K | 320,987 | D | ↗ |
| 2026-01-06 | Flammer Martina M.D. | Officer | M-Exempt | D | Stock Option (right to buy) | 8,570 | 26.43 | 226.5K | 0 | D | ↗ |
| 2026-01-06 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 1,517 | 173.33 | 262.9K | 83,631 | D | ↗ |
| 2026-01-06 | Adsett Roger | Officer | S-Sale | D | Common Stock | 1,429 | 173.33 | 247.7K | 110,462 | D | ↗ |
| 2026-01-05 | Flammer Martina M.D. | Officer | M-Exempt | A | Common Stock | 4,358 | 19.74 | 86.0K | 99,112 | D | ↗ |
| 2026-01-02 | Smith Michael Alexander | Officer | A-Award | A | Common Stock | 5,293 | 0.00 | — | 60,195 | D | ↗ |
| 2026-01-02 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 9,125 | 177.17 | 1.62M | 41,954 | D | ↗ |
| 2026-01-02 | Lewis William | Director / Officer | A-Award | A | Stock Option (right to buy) | 110,400 | 177.12 | 19.55M | 110,400 | D | ↗ |
| 2026-01-02 | Flammer Martina M.D. | Officer | A-Award | A | Common Stock | 5,998 | 0.00 | — | 89,109 | D | ↗ |
| 2026-01-02 | Bonstein Sara | Officer | A-Award | A | Stock Option (right to buy) | 31,280 | 177.12 | 5.54M | 31,280 | D | ↗ |
| 2026-01-02 | Adsett Roger | Officer | A-Award | A | Stock Option (right to buy) | 31,280 | 177.12 | 5.54M | 31,280 | D | ↗ |
| 2025-12-18 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 1,431 | 167.29 | 239.4K | 308,437 | D | ↗ |
| 2025-12-05 | SHAROKY MELVIN MD | Director | S-Sale | D | Common Stock | 20,000 | 205.01 | 4.10M | 243,948 | D | ↗ |
| 2025-12-04 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 2,222 | 205.66 | 457.0K | 307,872 | D | ↗ |
| 2025-12-01 | Flammer Martina M.D. | Officer | M-Exempt | D | Stock Option (right to buy) | 8,895 | 25.83 | 229.8K | 44,475 | D | ↗ |
| 2025-11-24 | ANDERSON ELIZABETH M | Director | S-Sale | D | Common Stock | 5,000 | 204.58 | 1.02M | 58,729 | D | ↗ |
| 2025-11-17 | LEE LEO | Director | S-Sale | D | Common Stock | 3,212 | 193.51 | 621.6K | 126,465 | D | ↗ |
| 2025-11-14 | ANDERSON ELIZABETH M | Director | S-Sale | D | Common Stock | 10,000 | 195.87 | 1.96M | 63,729 | D | ↗ |
| 2025-11-12 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 19,183 | 194.44 | 3.73M | 36,625 | D | ↗ |
| 2025-11-11 | Flammer Martina M.D. | Officer | M-Exempt | A | Common Stock | 18,277 | 18.95 | 346.3K | 114,337 | D | ↗ |
| 2025-11-06 | Brennan David R | Director | G-Gift | D | Common Stock | 60,000 | 0.00 | — | 66,933 | D | ↗ |
| 2025-11-03 | Smith Michael Alexander | Officer | M-Exempt | A | Common Stock | 27,130 | 23.75 | 644.3K | 82,032 | D | ↗ |
| 2025-09-12 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 6,158 | 147.46 | 908.1K | 36,461 | D | ↗ |
| 2025-09-12 | SHAROKY MELVIN MD | Director | S-Sale | D | Common Stock | 10,000 | 145.39 | 1.45M | 262,675 | D | ↗ |
| 2025-09-11 | SHAROKY MELVIN MD | Director | G-Gift | A | Common Stock | 159 | 0.00 | — | 272,675 | D | ↗ |
| 2025-09-04 | Schaeffer Orlov S Nicole | Officer | G-Gift | D | Common Stock | 23,303 | 0.00 | — | 56,461 | D | ↗ |
| 2025-09-02 | Smith Michael Alexander | Officer | M-Exempt | D | Stock Option (right to buy) | 12,780 | 30.46 | 389.3K | 0 | D | ↗ |
| 2025-09-02 | Flammer Martina M.D. | Officer | M-Exempt | D | Stock Option (right to buy) | 17,790 | 25.83 | 459.5K | 53,370 | D | ↗ |
| 2025-08-20 | SHAROKY MELVIN MD | Director | S-Sale | D | Common Stock | 10,000 | 129.50 | 1.30M | 274,516 | D | ↗ |
| 2025-08-19 | Adsett Roger | Officer | S-Sale | D | Common Stock | 4,807 | 128.27 | 616.6K | 105,637 | D | ↗ |
| 2025-08-18 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 6,865 | 10.85 | 74.5K | 240,789 | I | ↗ |
| 2025-08-14 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 3,554 | 126.57 | 449.8K | 86,210 | D | ↗ |
| 2025-08-13 | SHAROKY MELVIN MD | Director | G-Gift | D | Common Stock | 6,100 | 0.00 | — | 284,516 | D | ↗ |
| 2025-08-12 | SHAROKY MELVIN MD | Director | S-Sale | D | Common Stock | 10,000 | 121.58 | 1.22M | 290,616 | D | ↗ |
| 2025-08-04 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 1,938 | 110.91 | 214.9K | 233,924 | I | ↗ |
| 2025-08-04 | Flammer Martina M.D. | Officer | M-Exempt | D | Stock Option (right to buy) | 8,715 | 19.74 | 172.0K | 26,145 | D | ↗ |
| 2025-07-21 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 26,310 | 103.03 | 2.71M | 73,505 | D | ↗ |
| 2025-07-15 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 933 | 102.51 | 95.6K | 66,394 | D | ↗ |
| 2025-07-15 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 6,830 | 10.85 | 74.1K | 240,754 | I | ↗ |
| 2025-07-11 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 748 | 96.41 | 72.1K | 67,327 | D | ↗ |
| 2025-07-07 | Bonstein Sara | Officer | M-Exempt | A | Common Stock | 6,244 | 19.74 | 123.3K | 100,137 | D | ↗ |
| 2025-07-01 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 2,349 | 98.83 | 232.2K | 234,739 | I | ↗ |
| 2025-06-23 | Bonstein Sara | Officer | M-Exempt | A | Common Stock | 12,636 | 19.74 | 249.4K | 151,301 | D | ↗ |
| 2025-06-16 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 904 | 101.39 | 91.7K | 303,554 | D | ↗ |
| 2025-06-16 | Adsett Roger | Officer | S-Sale | D | Common Stock | 4,186 | 99.32 | 415.8K | 130,637 | D | ↗ |
| 2025-06-11 | Schaeffer Orlov S Nicole | Officer | M-Exempt | D | Stock Option (right to buy) | 70,000 | 13.91 | 973.7K | 87,290 | D | ↗ |
| 2025-06-11 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 19,423 | 94.50 | 1.84M | 83,111 | D | ↗ |
| 2025-06-10 | Schaeffer Orlov S Nicole | Officer | M-Exempt | D | Stock Option (right to buy) | 38,300 | 17.16 | 657.2K | 0 | D | ↗ |
| 2025-06-10 | Flammer Martina M.D. | Officer | M-Exempt | D | Stock Option (right to buy) | 25,740 | 26.46 | 681.1K | 17,160 | D | ↗ |
| 2025-06-10 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 15,825 | 89.85 | 1.42M | 109,840 | D | ↗ |
| 2025-06-05 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 1,879 | 73.50 | 138.1K | 67,718 | D | ↗ |
| 2025-06-04 | MCGIRR DAVID W J | Director | S-Sale | D | Common Stock | 3,000 | 73.27 | 219.8K | 97,723 | D | ↗ |
| 2025-06-03 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 1,448 | 71.50 | 103.5K | 69,597 | D | ↗ |
| 2025-06-03 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 1,642 | 71.50 | 117.4K | 118,579 | D | ↗ |
| 2025-06-03 | MCGIRR DAVID W J | Director | S-Sale | D | Common Stock | 3,250 | 71.30 | 231.7K | 100,723 | D | ↗ |
| 2025-06-03 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 5,472 | 71.50 | 391.2K | 308,758 | D | ↗ |
| 2025-06-03 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 1,686 | 71.50 | 120.5K | 83,111 | D | ↗ |
| 2025-06-03 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 1,579 | 71.50 | 112.9K | 113,288 | D | ↗ |
| 2025-06-03 | Adsett Roger | Officer | S-Sale | D | Common Stock | 1,860 | 71.50 | 133.0K | 141,323 | D | ↗ |
| 2025-06-02 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 6,830 | 10.85 | 74.1K | 240,754 | I | ↗ |
| 2025-05-30 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 6,327 | 68.56 | 433.8K | 91,045 | D | ↗ |
| 2025-05-27 | SHAROKY MELVIN MD | Director | G-Gift | D | Common Stock | 200 | 0.00 | — | 300,616 | D | ↗ |
| 2025-05-21 | Desjardins Clarissa | Director | P-Purchase | A | Common Stock | 1,130 | 66.35 | 75.0K | 3,025 | I | ↗ |
| 2025-05-20 | SHAROKY MELVIN MD | Director | G-Gift | D | Common Stock | 400 | 0.00 | — | 300,816 | D | ↗ |
| 2025-05-20 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 2,251 | 68.13 | 153.4K | 235,640 | I | ↗ |
| 2025-05-20 | Desjardins Clarissa | Director | P-Purchase | A | Common Stock | 1,895 | 66.87 | 126.7K | 1,895 | I | ↗ |
| 2025-05-16 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 1,799 | 67.53 | 121.5K | 84,797 | D | ↗ |
| 2025-05-15 | Smith Michael Alexander | Officer | A-Award | A | Common Stock | 5,578 | 0.00 | — | 97,372 | D | ↗ |
| 2025-05-15 | Schaeffer Orlov S Nicole | Officer | A-Award | A | Common Stock | 5,578 | 0.00 | — | 120,221 | D | ↗ |
| 2025-05-15 | SHAROKY MELVIN MD | Director | A-Award | A | Common Stock | 5,058 | 0.00 | — | 301,216 | D | ↗ |
| 2025-05-15 | SCHAFER CAROL | Director | A-Award | A | Common Stock | 5,058 | 0.00 | — | 63,317 | D | ↗ |
| 2025-05-15 | MCGIRR DAVID W J | Director | A-Award | A | Common Stock | 5,058 | 0.00 | — | 103,973 | D | ↗ |
| 2025-05-15 | Lewis William | Director / Officer | A-Award | A | Common Stock | 22,314 | 0.00 | — | 335,287 | D | ↗ |
| 2025-05-15 | LEE LEO | Director | A-Award | A | Common Stock | 5,058 | 0.00 | — | 129,677 | D | ↗ |
| 2025-05-15 | Flammer Martina M.D. | Officer | A-Award | A | Stock Option (right to buy) | 31,610 | 67.22 | 2.12M | 31,610 | D | ↗ |
| 2025-05-15 | Desjardins Clarissa | Director | A-Award | A | Common Stock | 5,058 | 0.00 | — | 67,007 | D | ↗ |
| 2025-05-15 | Brennan David R | Director | A-Award | A | Common Stock | 5,058 | 0.00 | — | 126,933 | D | ↗ |
| 2025-05-15 | Bonstein Sara | Officer | A-Award | A | Common Stock | 6,508 | 0.00 | — | 114,867 | D | ↗ |
| 2025-05-15 | Adsett Roger | Officer | A-Award | A | Stock Option (right to buy) | 31,610 | 67.22 | 2.12M | 31,610 | D | ↗ |
| 2025-05-15 | ANDERSON ELIZABETH M | Director | A-Award | A | Common Stock | 5,058 | 0.00 | — | 73,729 | D | ↗ |
| 2025-05-14 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 409 | 65.61 | 26.8K | 91,794 | D | ↗ |
| 2025-05-14 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 1,236 | 65.61 | 81.1K | 114,643 | D | ↗ |
| 2025-05-14 | SHAROKY MELVIN MD | Director | G-Gift | A | Common Stock | 576 | 0.00 | — | 576 | I | ↗ |
| 2025-05-14 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 3,771 | 65.61 | 247.4K | 312,973 | D | ↗ |
| 2025-05-14 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 1,744 | 65.61 | 114.4K | 90,013 | D | ↗ |
| 2025-05-14 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 1,634 | 65.61 | 107.2K | 108,359 | D | ↗ |
| 2025-05-14 | Adsett Roger | Officer | S-Sale | D | Common Stock | 1,925 | 65.61 | 126.3K | 136,675 | D | ↗ |
| 2025-05-13 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 4,407 | 67.81 | 298.8K | 92,203 | D | ↗ |
| 2025-05-13 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 4,999 | 67.81 | 339.0K | 115,879 | D | ↗ |
| 2025-05-13 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 7,699 | 67.70 | 521.2K | 316,744 | D | ↗ |
| 2025-05-13 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 8,408 | 67.81 | 570.1K | 91,757 | D | ↗ |
| 2025-05-13 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 8,870 | 67.81 | 601.5K | 109,993 | D | ↗ |
| 2025-05-13 | Adsett Roger | Officer | S-Sale | D | Common Stock | 7,482 | 67.81 | 507.4K | 138,600 | D | ↗ |
| 2025-05-01 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 4,201 | 72.78 | 305.7K | 233,924 | I | ↗ |
| 2025-04-15 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 6,830 | 10.85 | 74.1K | 240,754 | I | ↗ |
| 2025-04-01 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 772 | 73.44 | 56.7K | 236,961 | I | ↗ |
| 2025-03-17 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 18,750 | 22.76 | 426.8K | 352,936 | D | ↗ |
| 2025-03-03 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 377 | 79.73 | 30.1K | 233,970 | I | ↗ |
| 2025-02-25 | SHAROKY MELVIN MD | Director | G-Gift | D | Common Stock | 1,443 | 0.00 | — | 296,734 | D | ↗ |
| 2025-02-18 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 6,074 | 81.07 | 492.4K | 234,224 | I | ↗ |
| 2025-02-18 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 700 | 81.00 | 56.7K | 118,863 | D | ↗ |
| 2025-02-12 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 5,019 | 80.00 | 401.5K | 137,185 | D | ↗ |
| 2025-02-11 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 13,302 | 80.00 | 1.06M | 142,204 | D | ↗ |
| 2025-02-10 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 9,729 | 77.02 | 749.3K | 128,264 | D | ↗ |
| 2025-02-10 | Adsett Roger | Officer | S-Sale | D | Common Stock | 5,781 | 78.36 | 453.0K | 172,223 | D | ↗ |
| 2025-02-07 | Wise John Drayton | Officer | S-Sale | D | Common Stock | 10 | 78.91 | 789.10 | 133,015 | D | ↗ |
| 2025-02-07 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 60 | 79.59 | 4.8K | 137,993 | D | ↗ |
| 2025-02-07 | Adsett Roger | Officer | S-Sale | D | Common Stock | 100 | 79.57 | 8.0K | 189,057 | D | ↗ |
| 2025-02-06 | Wise John Drayton | Officer | S-Sale | D | Common Stock | 7,910 | 80.90 | 639.9K | 133,025 | D | ↗ |
| 2025-02-06 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 20,650 | 80.90 | 1.67M | 96,610 | D | ↗ |
| 2025-02-06 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 23,500 | 80.90 | 1.90M | 120,878 | D | ↗ |
| 2025-02-06 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 79,350 | 80.90 | 6.42M | 453,894 | D | ↗ |
| 2025-02-06 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 33,055 | 80.90 | 2.67M | 138,053 | D | ↗ |
| 2025-02-06 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 28,390 | 80.90 | 2.30M | 155,506 | D | ↗ |
| 2025-02-06 | Adsett Roger | Officer | S-Sale | D | Common Stock | 45,605 | 80.90 | 3.69M | 189,157 | D | ↗ |
| 2025-02-05 | Wise John Drayton | Officer | A-Award | A | Common Stock | 15,373 | 0.00 | — | 140,935 | D | ↗ |
| 2025-02-05 | Smith Michael Alexander | Officer | A-Award | A | Common Stock | 47,295 | 0.00 | — | 117,260 | D | ↗ |
| 2025-02-05 | Schaeffer Orlov S Nicole | Officer | A-Award | A | Common Stock | 47,295 | 0.00 | — | 144,378 | D | ↗ |
| 2025-02-05 | Lewis William | Director / Officer | A-Award | A | Common Stock | 153,710 | 0.00 | — | 533,244 | D | ↗ |
| 2025-02-05 | Flammer Martina M.D. | Officer | A-Award | A | Common Stock | 70,943 | 0.00 | — | 171,108 | D | ↗ |
| 2025-02-05 | Bonstein Sara | Officer | A-Award | A | Common Stock | 65,033 | 0.00 | — | 183,896 | D | ↗ |
| 2025-02-05 | Adsett Roger | Officer | A-Award | A | Common Stock | 88,680 | 0.00 | — | 234,762 | D | ↗ |
| 2025-02-03 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 6,830 | 10.85 | 74.1K | 240,754 | I | ↗ |
| 2025-01-30 | Schaeffer Orlov S Nicole | Officer | M-Exempt | D | Stock Option (right to buy) | 41,140 | 13.67 | 562.4K | 0 | D | ↗ |
| 2025-01-15 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 2,473 | 71.05 | 175.7K | 379,534 | D | ↗ |
| 2025-01-14 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 872 | 68.72 | 59.9K | 97,083 | D | ↗ |
| 2025-01-14 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 1,384 | 68.72 | 95.1K | 100,165 | D | ↗ |
| 2025-01-14 | Adsett Roger | Officer | S-Sale | D | Common Stock | 1,457 | 68.72 | 100.1K | 146,082 | D | ↗ |
| 2025-01-10 | Wise John Drayton | Officer | S-Sale | D | Common Stock | 287 | 65.40 | 18.8K | 125,562 | D | ↗ |
| 2025-01-10 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 319 | 63.38 | 20.2K | 69,965 | D | ↗ |
| 2025-01-10 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 3,092 | 63.62 | 196.7K | 97,955 | D | ↗ |
| 2025-01-10 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 2,978 | 63.36 | 188.7K | 392,589 | D | ↗ |
| 2025-01-10 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 4,801 | 63.62 | 305.4K | 101,549 | D | ↗ |
| 2025-01-10 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 1,066 | 63.72 | 67.9K | 118,863 | D | ↗ |
| 2025-01-10 | Adsett Roger | Officer | S-Sale | D | Common Stock | 3,604 | 63.62 | 229.3K | 147,539 | D | ↗ |
| 2025-01-08 | Wise John Drayton | Officer | A-Award | A | Stock Option (right to buy) | 31,930 | 65.72 | 2.10M | 31,930 | D | ↗ |
| 2025-01-08 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 1,064 | 66.21 | 70.4K | 64,578 | D | ↗ |
| 2025-01-08 | Schaeffer Orlov S Nicole | Officer | A-Award | A | Stock Option (right to buy) | 27,370 | 65.72 | 1.80M | 27,370 | D | ↗ |
| 2025-01-08 | Lewis William | Director / Officer | A-Award | A | Stock Option (right to buy) | 109,490 | 65.72 | 7.20M | 109,490 | D | ↗ |
| 2025-01-08 | Flammer Martina M.D. | Officer | A-Award | A | Common Stock | 6,657 | 0.00 | — | 107,721 | D | ↗ |
| 2025-01-08 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 1,464 | 66.05 | 96.7K | 113,272 | D | ↗ |
| 2025-01-08 | Adsett Roger | Officer | S-Sale | D | Common Stock | 1,882 | 66.10 | 124.4K | 145,784 | D | ↗ |
| 2025-01-07 | Wise John Drayton | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 16.07 | 160.7K | 0 | D | ↗ |
| 2025-01-07 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 2,306 | 65.98 | 152.1K | 65,642 | D | ↗ |
| 2025-01-07 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 2,596 | 65.88 | 171.0K | 97,515 | D | ↗ |
| 2025-01-07 | Lewis William | Director / Officer | S-Sale | D | Common Stock | 8,218 | 66.02 | 542.6K | 376,742 | D | ↗ |
| 2025-01-07 | Flammer Martina M.D. | Officer | S-Sale | D | Common Stock | 3,344 | 65.91 | 220.4K | 102,766 | D | ↗ |
| 2025-01-07 | Bonstein Sara | Officer | S-Sale | D | Common Stock | 3,470 | 65.70 | 228.0K | 114,736 | D | ↗ |
| 2025-01-07 | Adsett Roger | Officer | S-Sale | D | Common Stock | 2,444 | 65.95 | 161.2K | 147,666 | D | ↗ |
| 2025-01-02 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 6,830 | 10.85 | 74.1K | 240,754 | I | ↗ |
| 2024-12-19 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 18,750 | 22.76 | 426.8K | 403,710 | D | ↗ |
| 2024-12-12 | Lewis William | Director / Officer | M-Exempt | A | Common Stock | 6,830 | 10.85 | 74.1K | 240,754 | I | ↗ |
| 2024-09-16 | Flammer Martina M.D. | Officer | M-Exempt | D | Stock Option (right to buy) | 13,436 | 34.03 | 457.2K | 13,680 | — | ↗ |
| 2024-09-13 | Smith Michael Alexander | Officer | M-Exempt | A | Common Stock | 7,000 | 22.76 | 159.3K | 95,727 | — | ↗ |
| 2024-09-13 | Flammer Martina M.D. | Officer | M-Exempt | A | Common Stock | 26,969 | 34.03 | 917.8K | 133,103 | — | ↗ |
| 2024-09-12 | Flammer Martina M.D. | Officer | M-Exempt | D | Stock Option (right to buy) | 635 | 34.03 | 21.6K | 54,085 | — | ↗ |
| 2024-09-10 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 9,582 | 71.88 | 688.8K | 100,100 | — | ↗ |
| 2024-09-06 | Flammer Martina M.D. | Officer | M-Exempt | D | Stock Option (right to buy) | 14,130 | 23.75 | 335.6K | 0 | — | ↗ |
| 2024-08-29 | SHAROKY MELVIN MD | Director | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 298,177 | — | ↗ |
| 2024-08-12 | Smith Michael Alexander | Officer | S-Sale | D | Common Stock | 20,415 | 73.65 | 1.50M | 88,727 | — | ↗ |
| 2024-08-12 | Schaeffer Orlov S Nicole | Officer | S-Sale | D | Common Stock | 9,469 | 72.49 | 686.4K | 100,100 | — | ↗ |
| 2024-07-08 | Smith Michael Alexander | Officer | F-InKind | D | Common Stock | 730 | 70.05 | 51.1K | 88,727 | — | ↗ |
| 2024-06-10 | Flammer Martina M.D. | Officer | M-Exempt | A | Common Stock | 21,195 | 23.75 | 503.4K | 127,329 | — | ↗ |
| 2024-06-03 | Schaeffer Orlov S Nicole | Officer | M-Exempt | D | Stock Option (right to buy) | 13,750 | 16.07 | 221.0K | 0 | — | ↗ |
| 2024-05-30 | Flammer Martina M.D. | Officer | M-Exempt | D | Stock Option (right to buy) | 21,195 | 23.75 | 503.4K | 35,325 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-934.7K
Shares Outstanding
215.85M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | William H. Lewis CEO | 854.6K | — | 3.00M | 9.00M | 1.50M | 117.4K | 14.47M | 82.94% | ↗ |
| 2 | 2025 | Martina Flammer, M.D. Chief Medical Officer | 634.2K | — | 875.0K | 2.62M | 554.9K | 27.7K | 4.72M | 74.20% | ↗ |
| 3 | 2025 | Roger Adsett Chief Operating Officer | 622.6K | — | 875.0K | 2.62M | 544.8K | 24.3K | 4.69M | 74.60% | ↗ |
| 4 | 2025 | Sara Bonstein Chief Financial Officer | 583.2K | — | 875.0K | 2.62M | 510.3K | 24.2K | 4.62M | 75.79% | ↗ |
| 5 | 2025 | Michael A. Smith Chief Legal Officer | 595.3K | — | 750.0K | 2.25M | 520.9K | 22.0K | 4.14M | 72.50% | ↗ |
| 6 | 2024 | William H. Lewis CEO | 810.0K | — | 2.21M | 6.62M | 1.22M | 93.6K | 10.94M | 80.64% | ↗ |
| 7 | 2024 | Roger Adsett Chief Operating Officer | 598.6K | — | 750.0K | 2.25M | 561.2K | 96.5K | 4.26M | 70.48% | ↗ |
| 8 | 2024 | Martina Flammer, M.D. Chief Medical Officer | 576.5K | 16.2K | 750.0K | 2.25M | 502.7K | 19.4K | 4.11M | 72.91% | ↗ |
| 9 | 2024 | Drayton Wise Chief Commercial Officer | 551.2K | — | 750.0K | 2.25M | 465.1K | 93.4K | 4.11M | 73.00% | ↗ |
| 10 | 2024 | Sara Bonstein Chief Financial Officer | 530.2K | — | 750.0K | 2.25M | 462.3K | 19.5K | 4.01M | 74.78% | ↗ |
| 11 | 2023 | William H. Lewis CEO | 780.0K | — | 2.21M | 6.62M | 702.0K | 106.4K | 10.41M | 84.74% | ↗ |
| 12 | 2023 | Sara Bonstein Chief Financial Officer | 511.0K | — | 1.31M | 2.44M | 276.0K | 23.4K | 4.56M | 82.23% | ↗ |
| 13 | 2023 | Martina Flammer, M.D. Chief Medical Officer | 555.7K | — | 1.10M | 2.25M | 300.1K | 16.5K | 4.22M | 79.34% | ↗ |
| 14 | 2023 | Roger Adsett Chief Operating Officer | 577.0K | — | 750.0K | 2.25M | 346.2K | 85.3K | 4.01M | 74.84% | ↗ |
| 15 | 2023 | Drayton Wise Chief Commercial Officer | 530.0K | — | 750.0K | 2.25M | 292.2K | 66.6K | 3.89M | 77.08% | ↗ |
| 16 | 2022 | William H. Lewis President and CEO | 734.9K | — | 1.62M | 4.87M | 514.4K | 42.7K | 7.79M | 83.42% | ↗ |
| 17 | 2022 | William H. Lewis CEO | 734.9K | — | 1.62M | 4.87M | 514.4K | 42.7K | 7.79M | 83.42% | ↗ |
| 18 | 2022 | Roger Adsett Chief Operating Officer | 560.2K | — | 937.5K | 2.81M | 262.6K | 71.9K | 4.64M | 80.73% | ↗ |
| 19 | 2022 | Drayton Wise Chief Commercial Officer | 478.6K | — | 687.5K | 2.58M | 200.0K | 71.4K | 4.02M | 81.33% | ↗ |
| 20 | 2022 | Martina Flammer, M.D. Chief Medical Officer | 534.3K | — | 750.0K | 2.25M | 213.8K | 15.5K | 3.76M | 79.71% | ↗ |
| 21 | 2022 | Sara Bonstein Chief Financial Officer | 477.6K | — | 687.5K | 2.06M | 191.1K | 15.5K | 3.43M | 80.07% | ↗ |
| 22 | 2021 | William H. Lewis President and CEO | 710.0K | — | 1.50M | 4.50M | 601.4K | 11.6K | 7.32M | 81.93% | ↗ |
| 23 | 2021 | William H. Lewis CEO | 710.0K | — | 1.50M | 4.50M | 601.4K | 11.6K | 7.32M | 81.93% | ↗ |
| 24 | 2021 | Roger Adsett Chief Operating Officer | 529.7K | — | 750.0K | 2.25M | 326.5K | 14.9K | 3.87M | 77.50% | ↗ |
| 25 | 2021 | Martina Flammer, M.D. Chief Medical Officer | 517.5K | — | 750.0K | 2.25M | 255.2K | 14.9K | 3.79M | 79.20% | ↗ |
| 26 | 2021 | Sara Bonstein Chief Financial Officer | 460.3K | — | 687.5K | 2.06M | 227.0K | 14.9K | 3.45M | 79.66% | ↗ |
| 27 | 2021 | Christine Pellizzari Former Chief Legal Officer | 254.6K | — | 625.0K | 1.87M | — | 91.6K | 2.85M | 87.83% | ↗ |
| 28 | 2021 | S. Nicole Schaeffer Chief People Strategy Officer | 432.6K | — | 500.0K | 1.50M | 213.3K | 14.9K | 2.66M | 75.16% | ↗ |
| 29 | 2020 | William H. Lewis President and CEO | 659.7K | — | 1.25M | 3.75M | 514.6K | 11.4K | 6.19M | 80.83% | ↗ |
| 30 | 2020 | Martina Flammer, M.D. Chief Medical Officer | 500.0K | 150.0K | 250.0K | 2.75M | 267.6K | 16.8K | 3.93M | 76.25% | ↗ |
| 31 | 2020 | Roger Adsett Chief Operating Officer | 514.3K | — | 625.0K | 1.88M | 264.9K | 14.7K | 3.29M | 75.90% | ↗ |
| 32 | 2020 | Christine Pellizzari Former Chief Legal Officer | 476.2K | — | 625.0K | 1.88M | 245.3K | 11.4K | 3.23M | 77.33% | ↗ |
| 33 | 2020 | Christine Pellizzari Chief Legal Officer | 476.2K | — | 625.0K | 1.88M | 245.3K | 11.4K | 3.23M | 77.33% | ↗ |
| 34 | 2020 | Sara Bonstein Chief Financial Officer | 386.6K | 75.0K | — | 2.02M | 224.7K | 11.4K | 2.72M | 74.37% | ↗ |
| 35 | 2020 | S. Nicole Schaeffer Chief People Strategy Officer | 412.0K | — | 250.0K | 750.0K | 220.5K | 14.7K | 1.65M | 60.71% | ↗ |
| 36 | 2020 | John Goll Interim Principal Financial Officer (2019-2020) | 345.1K | — | 125.0K | 375.0K | 151.0K | 17.3K | 1.01M | 49.34% | ↗ |
| 37 | 2019 | William H. Lewis President and CEO | 640.5K | — | 1.50M | 4.50M | 472.7K | 62.0K | 7.18M | 83.62% | ↗ |
| 38 | 2019 | Roger Adsett Chief Operating Officer | 475.7K | — | 1.12M | 1.87M | 237.9K | 14.8K | 3.73M | 80.46% | ↗ |
| 39 | 2019 | Christine Pellizzari Former Chief Legal Officer | 449.2K | — | 750.0K | 1.27M | 224.2K | 11.2K | 2.71M | 74.73% | ↗ |
| 40 | 2019 | Christine Pellizzari Chief Legal Officer | 449.2K | — | 750.0K | 1.27M | 224.2K | 11.2K | 2.71M | 74.73% | ↗ |
| 41 | 2019 | S. Nicole Schaeffer Chief People Strategy Officer | 400.0K | — | 425.0K | 1.27M | 196.9K | 15.7K | 2.31M | 73.51% | ↗ |
| 42 | 2019 | Paolo Tombesi Former Chief Financial Officer | 190.0K | — | — | 975.0K | — | 362.4K | 1.53M | 63.84% | ↗ |
| 43 | 2019 | John Goll Interim Principal Financial Officer (2019-2020) | 330.6K | — | 125.0K | 225.0K | 140.5K | 11.2K | 832.3K | 42.05% | ↗ |
| 44 | 2019 | John Goll Former Principal Financial Officer | 330.6K | — | 125.0K | 225.0K | 140.5K | 11.2K | 832.3K | 42.05% | ↗ |
| 45 | 2019 | Martina Flammer, M.D. Chief Medical Officer | 20.8K | — | — | — | — | 59.4K | 80.2K | 0.00% | ↗ |
| 46 | 2018 | William H. Lewis President and CEO | 610.0K | — | 1.17M | 3.52M | 622.2K | 11.0K | 5.94M | 79.08% | ↗ |
| 47 | 2018 | Roger Adsett Chief Commercial Officer | 458.3K | — | 475.0K | 1.43M | 300.2K | 14.7K | 2.67M | 71.08% | ↗ |
| 48 | 2018 | Roger Adsett Chief Operating Officer | 458.3K | — | 475.0K | 1.43M | 300.2K | 14.7K | 2.67M | 71.08% | ↗ |
| 49 | 2018 | Paul Streck Former Chief Medical Officer | 439.1K | — | 450.0K | 1.05M | 283.3K | 11.2K | 2.23M | 67.15% | ↗ |
| 50 | 2018 | Christine Pellizzari Chief Legal Officer | 436.1K | — | 325.0K | 975.0K | 283.5K | 11.0K | 2.03M | 64.02% | ↗ |
| 51 | 2018 | Paolo Tombesi Former Chief Financial Officer | 442.6K | — | 325.0K | 975.0K | 270.0K | 11.2K | 2.02M | 64.23% | ↗ |
| 52 | 2018 | Paolo Tombesi Chief Financial Officer | 442.6K | — | 325.0K | 975.0K | 270.0K | 11.2K | 2.02M | 64.23% | ↗ |
| 53 | 2018 | S. Nicole Schaeffer Chief People Strategy Officer | 375.9K | — | 325.0K | 975.0K | 244.4K | 14.5K | 1.93M | 67.19% | ↗ |
| 54 | 2018 | John Goll Interim Principal Financial Officer (2019-2020) | 306.5K | — | 68.7K | 206.3K | 171.1K | 11.0K | 763.6K | 36.01% | ↗ |
| 55 | 2018 | John Goll Former Principal Financial Officer | 306.5K | — | 68.7K | 206.3K | 171.1K | 11.0K | 763.6K | 36.01% | ↗ |
| 56 | 2017 | William H. Lewis President and CEO | 566.5K | — | — | 3.20M | 577.8K | 8.1K | 4.35M | 73.52% | ↗ |
| 57 | 2017 | Roger Adsett Chief Commercial Officer | 436.5K | — | — | 1.61M | 281.6K | 8.1K | 2.34M | 68.95% | ↗ |
| 58 | 2017 | Roger Adsett Chief Operating Officer | 436.5K | — | — | 1.61M | 281.6K | 8.1K | 2.34M | 68.95% | ↗ |
| 59 | 2017 | Christine Pellizzari Chief Legal Officer | 415.3K | — | — | 1.28M | 270.0K | 8.1K | 1.98M | 64.94% | ↗ |
| 60 | 2017 | Paolo Tombesi Chief Financial Officer | 253.8K | 40.0K | — | 1.30M | 277.4K | 12.1K | 1.88M | 69.03% | ↗ |
| 61 | 2017 | Paolo Tombesi Former Chief Financial Officer | 253.8K | 40.0K | — | 1.30M | 277.4K | 12.1K | 1.88M | 69.03% | ↗ |
| 62 | 2017 | S. Nicole Schaeffer Chief People Strategy Officer | 348.1K | — | — | 1.22M | 226.3K | 11.4K | 1.81M | 67.55% | ↗ |
| 63 | 2017 | Paul Streck Former Chief Medical Officer | 244.9K | 40.0K | — | 1.10M | 208.8K | 684.00 | 1.59M | 68.99% | ↗ |
| 64 | 2017 | Paul Streck Chief Medical Officer | 244.9K | 40.0K | — | 1.10M | 208.8K | 684.00 | 1.59M | 68.99% | ↗ |
| 65 | 2017 | John Goll Former Principal Financial Officer | 297.6K | 100.0K | — | 275.0K | 161.5K | 8.1K | 842.1K | 32.65% | ↗ |
| 66 | 2017 | Andrew T. Drechsler Former Chief Financial Officer | 97.6K | — | — | — | — | 3.9K | 101.5K | 0.00% | ↗ |
| 67 | 2016 | William H. Lewis President and CEO | 550.0K | — | — | 3.60M | 330.0K | 8.0K | 4.48M | 80.19% | ↗ |
| 68 | 2016 | Eugene J. Sullivan Chief Medical and Scientific Officer | 412.0K | — | — | 1.10M | 158.7K | 22.4K | 1.69M | 64.98% | ↗ |
| 69 | 2016 | Christine Pellizzari Chief Legal Officer | 394.6K | — | — | 1.10M | 169.7K | 8.0K | 1.67M | 65.79% | ↗ |
| 70 | 2016 | Christine Pellizzari General Counsel and Corporate Secretary | 394.6K | — | — | 1.10M | 169.7K | 8.0K | 1.67M | 65.79% | ↗ |
| 71 | 2016 | Andrew T. Drechsler Former Chief Financial Officer | 379.1K | — | — | 1.10M | 151.7K | 8.0K | 1.64M | 67.14% | ↗ |
| 72 | 2016 | S. Nicole Schaeffer Senior Vice President, Human Resources and Corporate Services | 322.3K | — | — | 1.10M | 129.0K | 8.0K | 1.56M | 70.56% | ↗ |
| 73 | 2016 | Roger Adsett Chief Commercial Officer | 114.1K | 25.0K | — | 1.28M | 86.0K | 3.6K | 1.51M | 84.86% | ↗ |
| 74 | 2015 | William H. Lewis President and Chief Executive Officer | 505.0K | — | — | 2.38M | 248.5K | 8.0K | 3.14M | 75.76% | ↗ |
| 75 | 2015 | William H. Lewis President and CEO | 505.0K | — | — | 2.38M | 248.5K | 8.0K | 3.14M | 75.76% | ↗ |
| 76 | 2015 | Eugene J. Sullivan Chief Medical and Scientific Officer | 310.8K | — | — | 1.84M | 134.4K | 43.6K | 2.33M | 79.05% | ↗ |
| 77 | 2015 | Christine Pellizzari General Counsel and Corporate Secretary | 365.4K | — | — | 880.0K | 132.0K | 8.0K | 1.39M | 63.52% | ↗ |
| 78 | 2015 | Christine Pellizzari Chief Legal Officer | 365.4K | — | — | 880.0K | 132.0K | 8.0K | 1.39M | 63.52% | ↗ |
| 79 | 2015 | Andrew T. Drechsler Former Chief Financial Officer | 351.0K | — | — | 880.0K | 119.7K | 8.0K | 1.36M | 64.77% | ↗ |
| 80 | 2015 | Andrew T. Drechsler Chief Financial Officer | 351.0K | — | — | 880.0K | 119.7K | 8.0K | 1.36M | 64.77% | ↗ |
| 81 | 2015 | S. Nicole Schaeffer Senior Vice President, Human Resources and Corporate Services | 312.9K | — | — | 806.7K | 96.2K | 8.0K | 1.22M | 65.92% | ↗ |
| 82 | 2014 | Peggy J. Berry Vice President, Regulatory | 275.6K | 35.0K | — | 1.56M | 100.2K | — | 1.97M | 79.16% | ↗ |
| 83 | 2014 | William H. Lewis President and CEO | 465.0K | — | — | 1.20M | 287.4K | — | 1.95M | 61.41% | ↗ |
| 84 | 2014 | William H. Lewis President and Chief Executive Officer | 465.0K | — | — | 1.20M | 287.4K | — | 1.95M | 61.41% | ↗ |
| 85 | 2014 | William H. Lewis President and Chief Executive Officer | 465.0K | — | — | 1.20M | 287.4K | — | 1.95M | 61.41% | ↗ |
| 86 | 2014 | Christine Pellizzari General Counsel and Corporate Secretary | 354.7K | — | — | 718.5K | 148.7K | — | 1.22M | 58.80% | ↗ |
| 87 | 2014 | Christine Pellizzari General Counsel and Corporate Secretary | 354.7K | — | — | 718.5K | 148.7K | — | 1.22M | 58.80% | ↗ |
| 88 | 2014 | Andrew T. Drechsler Former Chief Financial Officer | 340.8K | — | — | 718.5K | 142.8K | — | 1.20M | 59.77% | ↗ |
| 89 | 2014 | Andrew T. Drechsler Chief Financial Officer | 340.8K | — | — | 718.5K | 142.8K | — | 1.20M | 59.77% | ↗ |
| 90 | 2014 | Andrew T. Drechsler Chief Financial Officer | 340.8K | — | — | 718.5K | 142.8K | — | 1.20M | 59.77% | ↗ |
| 91 | 2014 | S. Nicole Schaeffer Senior Vice President, Human Resources and | 303.8K | — | — | 658.6K | 106.4K | — | 1.07M | 61.62% | ↗ |
| 92 | 2014 | S. Nicole Schaeffer Senior Vice President, Human Resources and Corporate Services | 303.8K | — | — | 658.6K | 106.4K | — | 1.07M | 61.62% | ↗ |
| 93 | 2013 | William H. Lewis President and Chief Executive Officer | 445.0K | — | — | 11.50M | 263.8K | — | 12.21M | 94.19% | ↗ |
| 94 | 2013 | William H. Lewis President and Chief Executive Officer | 445.0K | — | — | 11.50M | 263.8K | — | 12.21M | 94.19% | ↗ |
| 95 | 2013 | Matthew Pauls Chief Commercial Officer | 288.8K | — | — | 1.97M | 168.8K | — | 2.42M | 81.13% | ↗ |
| 96 | 2013 | Renu Gupta, M.D. Executive Vice President of Development and Chief | 422.2K | — | 174.5K | 1.48M | 168.2K | — | 2.25M | 73.75% | ↗ |
| 97 | 2013 | Andrew T. Drechsler Chief Financial Officer | 330.0K | — | — | 1.04M | 143.0K | — | 1.52M | 68.84% | ↗ |
| 98 | 2013 | Andrew T. Drechsler Chief Financial Officer | 330.0K | — | — | 1.04M | 143.0K | — | 1.52M | 68.84% | ↗ |
| 99 | 2013 | S. Nicole Schaeffer Senior Vice President, Human Resources and Corporate Services | 280.0K | — | — | 1.11M | 107.4K | — | 1.50M | 74.17% | ↗ |
| 100 | 2013 | S. Nicole Schaeffer Senior Vice President, Human Resources and | 280.0K | 107.4K | — | 1.11M | — | — | 1.50M | 74.17% | ↗ |
| 101 | 2013 | Christine Pellizzari General Counsel and Corporate Secretary | 149.9K | 15.0K | — | 1.25M | 63.2K | — | 1.48M | 84.58% | ↗ |
| 102 | 2013 | Christine Pellizzari General Counsel and Corporate Secretary | 149.9K | 15.0K | — | 1.25M | 63.2K | — | 1.48M | 84.58% | ↗ |
| 103 | 2013 | Peggy J. Berry Vice President, Regulatory | — | — | — | — | — | — | — | — | ↗ |
| 104 | 2012 | Will Lewis | 125.4K | 86.8K | — | 2.59M | — | 34.7K | 2.84M | 91.30% | ↗ |
| 105 | 2012 | William H. Lewis President and Chief Executive Officer | 125.4K | 86.8K | — | 2.59M | — | 34.7K | 2.84M | 91.30% | ↗ |
| 106 | 2012 | Timothy Whitten Former President and Chief Executive Officer | 293.1K | — | 442.7K | 199.3K | — | 939.8K | 1.87M | 34.24% | ↗ |
| 107 | 2012 | Nicholas A. LaBella, Jr. Former Chief Scientific Officer | 253.8K | — | 276.0K | 92.0K | — | 615.2K | 1.24M | 29.75% | ↗ |
| 108 | 2012 | Andrew T. Drechsler Chief Financial Officer | 52.7K | 35.0K | — | 917.0K | — | — | 1.00M | 91.27% | ↗ |
| 109 | 2012 | Andrew T. Drechsler Chief Financial Officer | 52.7K | 35.0K | — | — | — | — | 1.00M | 0.00% | ↗ |
| 110 | 2012 | Kevin P. Tully, C.G.A. Former Executive Vice President and Chief Financial Officer | 302.4K | — | 96.7K | 17.4K | — | 505.8K | 922.3K | 12.37% | ↗ |
| 111 | 2012 | Renu Gupta, M.D. Executive Vice President of Development and Chief Medical Officer | 406.0K | 189.8K | — | — | — | — | 595.8K | 0.00% | ↗ |
| 112 | 2012 | Renu Gupta, M.D. Executive Vice President of Development and Chief | 406.0K | 189.8K | — | — | — | — | 595.8K | 0.00% | ↗ |
| 113 | 2012 | Andrea Holtzman Drucker, J.D. Senior Vice President, General Counsel | 303.4K | 106.4K | — | — | — | — | 409.7K | 0.00% | ↗ |
| 114 | 2012 | Donald Hayden, Jr. | 64.6K | 36.0K | — | — | — | 5.4K | 106.0K | 0.00% | ↗ |
| 115 | 2012 | Matthew Pauls Chief Commercial Officer | — | — | — | — | — | — | — | — | ↗ |
| 116 | 2012 | Christine Pellizzari General Counsel and Corporate Secretary | — | — | — | — | — | — | — | — | ↗ |
| 117 | 2012 | S. Nicole Schaeffer Senior Vice President, Human Resources and | — | — | — | — | — | — | — | — | ↗ |
| 118 | 2012 | Peggy J. Berry Vice President, Regulatory | — | — | — | — | — | — | — | — | ↗ |
| 119 | 2011 | Timothy Whitten Former President and Chief Executive Officer | 425.0K | 106.3K | 1.35M | 312.4K | — | — | 2.20M | 75.82% | ↗ |
| 120 | 2011 | Renu Gupta, M.D. Executive Vice President of Development and Chief | 400.0K | 102.8K | 475.5K | 229.4K | — | — | 1.21M | 58.37% | ↗ |
| 121 | 2011 | Renu Gupta, M.D. Executive Vice President of Development and Chief Medical Officer | 400.0K | 102.8K | 475.5K | 229.4K | — | — | 1.21M | 58.37% | ↗ |
| 122 | 2011 | Kevin P. Tully, C.G.A. Former Executive Vice President and Chief Financial Officer | 325.0K | 78.6K | 475.5K | 135.4K | — | — | 1.01M | 60.22% | ↗ |
| 123 | 2011 | Nicholas A. LaBella, Jr. Former Chief Scientific Officer | 325.0K | 78.6K | 402.4K | 30.3K | — | — | 836.3K | 51.74% | ↗ |
| 124 | 2011 | Andrea Holtzman Drucker, J.D. Senior Vice President, General Counsel | 137.5K | 31.1K | 513.5K | 79.1K | — | — | 761.1K | 77.85% | ↗ |
| 125 | 2011 | William H. Lewis President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 126 | 2011 | Andrew T. Drechsler Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 127 | 2011 | Matthew Pauls Chief Commercial Officer | — | — | — | — | — | — | — | — | ↗ |
| 128 | 2011 | Christine Pellizzari General Counsel and Corporate Secretary | — | — | — | — | — | — | — | — | ↗ |
| 129 | 2010 | Kevin P. Tully, C.G.A. Former Executive Vice President and Chief Financial Officer | 278.2K | 111.3K | — | — | — | — | 389.4K | 0.00% | ↗ |
| 130 | 2010 | Timothy Whitten Former President and Chief Executive Officer | 35.4K | 112.5K | — | — | — | — | 147.9K | 0.00% | ↗ |
| 131 | 2010 | Renu Gupta, M.D. Executive Vice President of Development and Chief Medical Officer | 33.3K | 107.8K | — | — | — | — | 141.1K | 0.00% | ↗ |
| 132 | 2007 | Steve Glover President, Insmed Therapeutic Proteins (June 2007 – December 2007) | 145.4K | — | — | 46.8K | — | 75.0K | 267.2K | 17.52% | ↗ |
| 133 | 2007 | Doug Farrar Vice President, Insmed Therapeutic Proteins | 225.0K | — | — | 37.4K | — | — | 262.4K | 14.25% | ↗ |
| 134 | 2006 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer and President | 396.5K | — | — | 112.5K | — | 19.9K | 528.8K | 21.27% | ↗ |
| 135 | 2006 | Philip J. Young Executive Vice President and Chief Business Officer | 267.6K | — | — | 140.3K | — | — | 407.9K | 34.40% | ↗ |
| 136 | 2006 | Ronald D. Gunn, M.B.A., M.S. Executive Vice President and Chief Operating Officer | 270.9K | — | — | 59.0K | — | — | 329.9K | 17.89% | ↗ |
| 137 | 2006 | Thomas A. Keuer Sr. Vice President, Insmed Therapeutic Proteins | 201.5K | — | — | 63.4K | — | 8.7K | 273.5K | 23.18% | ↗ |
| 138 | 2006 | Kevin P. Tully, C.G.A. Executive Vice President and Chief Financial Officer (February 2006-December 2006) | 186.1K | — | — | 66.3K | — | — | 252.4K | 26.28% | ↗ |
| 139 | 2006 | Michael Duncan Principal Financial Officer (January 2006-February 2006) | 103.6K | — | — | 10.8K | — | — | 114.4K | 9.48% | ↗ |
| 140 | 2006 | Summary Compensation Table for Fiscal 2006 Name and Principal Position | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 200.00% | ↗ |
| 141 | 2005 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer and President | 395.2K | 197.6K | — | 312.5K | — | 2.1K | 594.9K | 52.53% | ↗ |
| 142 | 2005 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer | 395.2K | 197.6K | — | 312.5K | — | 2.1K | 594.9K | 52.53% | ↗ |
| 143 | 2005 | Ronald D. Gunn, M.B.A., M.S. Executive Vice President and Chief Operating Officer | 270.0K | 94.5K | — | 175.0K | — | 895.00 | 365.4K | 47.89% | ↗ |
| 144 | 2005 | Ronald D. Gunn, M.B.A., M.S. Executive Vice President and Chief Operating Officer | 270.0K | 94.5K | — | 175.0K | — | 895.00 | 365.4K | 47.89% | ↗ |
| 145 | 2005 | Philip J. Young Executive Vice President, | 250.0K | 87.5K | — | 125.0K | — | 822.00 | 338.3K | 36.95% | ↗ |
| 146 | 2005 | Andreas Sommer, Ph.D. Chief Scientific Officer | 260.0K | 26.0K | — | 50.0K | — | 2.2K | 288.2K | 17.35% | ↗ |
| 147 | 2005 | Andreas Sommer, Ph.D. Chief Scientific Officer | 260.0K | 26.0K | — | 50.0K | — | 2.2K | 288.2K | 17.35% | ↗ |
| 148 | 2005 | Thomas A. Keuer Senior Vice President, Insmed | 189.6K | 87.5K | — | 125.0K | — | 548.00 | 277.6K | 45.02% | ↗ |
| 149 | 2005 | Kevin P. Tully, C.G.A. Executive Vice President and Chief Financial Officer | 146.1K | — | — | — | — | 568.00 | 146.7K | 0.00% | ↗ |
| 150 | 2005 | Kevin P. Tully, C.G.A. Executive Vice President and Chief Financial Officer | 146.1K | — | — | — | — | 568.00 | 146.7K | 0.00% | ↗ |
| 151 | 2004 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer and President | 395.2K | 98.8K | — | — | — | 2.1K | 496.1K | 0.00% | ↗ |
| 152 | 2004 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer | 395.2K | 98.8K | — | — | — | 2.1K | 496.1K | 0.00% | ↗ |
| 153 | 2004 | Ronald D. Gunn, M.B.A., M.S. Executive Vice President and Chief Operating Officer | 261.9K | 65.5K | — | — | — | 597.00 | 327.9K | 0.00% | ↗ |
| 154 | 2004 | Ronald D. Gunn, M.B.A., M.S. Executive Vice President and Chief Operating Officer | 261.9K | 65.5K | — | — | — | 597.00 | 327.9K | 0.00% | ↗ |
| 155 | 2004 | Andreas Sommer, Ph.D. Chief Scientific Officer | 260.0K | 39.0K | — | — | — | 2.2K | 301.2K | 0.00% | ↗ |
| 156 | 2004 | Andreas Sommer, Ph.D. Chief Scientific Officer | 260.0K | 39.0K | — | — | — | 2.2K | 301.2K | 0.00% | ↗ |
| 157 | 2004 | Kevin P. Tully, C.G.A. Executive Vice President and Chief Financial Officer | 176.8K | 44.2K | — | — | — | 851.00 | 221.9K | 0.00% | ↗ |
| 158 | 2004 | Kevin P. Tully, C.G.A. Executive Vice President and Chief Financial Officer | 176.8K | 44.2K | — | — | — | 851.00 | 221.9K | 0.00% | ↗ |
| 159 | 2004 | Philip J. Young Executive Vice President, | 173.3K | 43.3K | — | 250.0K | — | 548.00 | 217.2K | 115.12% | ↗ |
| 160 | 2004 | Philip J. Young Chief Business Officer and Executive Vice President, Commercial Operations | 173.3K | 43.3K | — | — | — | 548.00 | 217.2K | 0.00% | ↗ |
| 161 | 2004 | Thomas A. Keuer Senior Vice President, Insmed | 122.6K | 24.5K | — | 130.0K | — | 365.00 | 147.5K | 88.12% | ↗ |
| 162 | 2003 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer and President | 395.2K | 197.6K | — | 150.0K | — | 2.1K | 594.9K | 25.22% | ↗ |
| 163 | 2003 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer | 395.2K | 197.6K | — | 150.0K | — | 2.1K | 594.9K | 25.22% | ↗ |
| 164 | 2003 | Andreas Sommer, Ph.D. Chief Scientific Officer | 260.0K | 26.0K | — | 100.0K | — | 2.2K | 288.2K | 34.70% | ↗ |
| 165 | 2003 | Ronald D. Gunn, M.B.A., M.S. Executive Vice President and Chief Operating Officer | 190.9K | 57.3K | — | 100.0K | — | 438.00 | 248.6K | 40.22% | ↗ |
| 166 | 2003 | Ronald D. Gunn, M.B.A., M.S. Executive Vice President and Chief Operating Officer | 190.9K | 57.3K | — | 100.0K | — | 438.00 | 248.6K | 40.22% | ↗ |
| 167 | 2003 | Kevin P. Tully, C.G.A. Executive Vice President and Chief Financial Officer | 176.8K | 35.4K | — | 100.0K | — | 851.00 | 213.0K | 46.95% | ↗ |
| 168 | 2003 | Kevin P. Tully, C.G.A. Executive Vice President and Chief Financial Officer | 176.8K | 35.4K | — | 100.0K | — | 851.00 | 213.0K | 46.95% | ↗ |
| 169 | 2002 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer and President | 395.2K | — | — | 300.0K | — | 1.4K | 396.6K | 75.65% | ↗ |
| 170 | 2002 | Andreas Sommer, Ph.D. Chief Scientific Officer | 260.0K | — | — | — | — | 2.2K | 262.2K | 0.00% | ↗ |
| 171 | 2002 | Ronald D. Gunn, M.B.A., M.S. Executive Vice President and Chief Operating Officer | 176.8K | — | — | — | — | 370.00 | 177.2K | 0.00% | ↗ |
| 172 | 2001 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer and President | 380.0K | 152.0K | — | 250.0K | — | 14.8K | 546.8K | 45.72% | ↗ |
| 173 | 2001 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer and President | 380.0K | 152.0K | — | 250.0K | — | 678.00 | 532.7K | 46.93% | ↗ |
| 174 | 2001 | Andreas Sommer, Ph.D Principal Scientist | 239.6K | — | — | 200.0K | — | 3.2K | 242.7K | 82.40% | ↗ |
| 175 | 2001 | Andreas Sommer, Ph.D. Chief Scientific Officer | 239.6K | — | — | 200.0K | — | 3.2K | 242.7K | 82.40% | ↗ |
| 176 | 2001 | Robert A. Falconer Vice President, Technical Operations | 170.0K | 42.5K | — | 225.0K | — | 530.00 | 213.0K | 105.62% | ↗ |
| 177 | 2001 | Ronald D. Gunn Vice President, Business Development | 170.0K | 42.5K | — | 225.0K | — | 353.00 | 212.9K | 105.71% | ↗ |
| 178 | 2001 | Ronald D. Gunn, M.B.A., M.S. Executive Vice President and Chief Operating Officer | 170.0K | 42.5K | — | 225.0K | — | 353.00 | 212.9K | 105.71% | ↗ |
| 179 | 2001 | Michael D. Baer Chief Financial Officer | 200.0K | — | — | 225.0K | — | 1.7K | 201.7K | 111.55% | ↗ |
| 180 | 2000 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer and President | 360.0K | 350.0K | — | 250.0K | — | 4.0K | 714.0K | 35.01% | ↗ |
| 181 | 2000 | Michael D. Baer Chief Financial Officer | 190.0K | 78.5K | — | 50.0K | — | 1.5K | 270.0K | 18.52% | ↗ |
| 182 | 2000 | Ronald D. Gunn Vice President, Business Development | 150.5K | 95.0K | — | 50.0K | — | 259.00 | 245.8K | 20.35% | ↗ |
| 183 | 2000 | Andreas Sommer, Ph.D Principal Scientist | 116.2K | — | — | 142.5K | — | 98.5K | 214.7K | 66.37% | ↗ |
| 184 | 2000 | Robert A. Falconer Vice President, Technical Operations | 150.7K | 45.0K | — | 50.0K | — | 457.00 | 196.2K | 25.49% | ↗ |
| 185 | 1999 | Geoffrey Allan, Ph.D. Chairman of the Board, Chief Executive Officer and President | 210.0K | 90.0K | — | 87.5K | — | 1.5K | 301.5K | 29.02% | ↗ |
| 186 | 1999 | Ronald D. Gunn Vice President, Business Development | 131.3K | 30.0K | — | — | — | 240.00 | 161.5K | 0.00% | ↗ |
| 187 | 1999 | Michael D. Baer Chief Financial Officer | 103.1K | 30.0K | — | — | — | 9.9K | 143.0K | 0.00% | ↗ |
| 188 | 1999 | Robert A. Falconer Vice President, Technical Operations | 6.3K | — | — | — | — | — | 6.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| William H. Lewis | President, Chief Executive Officer & Chairman | 2M | male |
| Martina Flammer | Chief Medical Officer | 1M | — |
| Roger Adsett | Chief Operating Officer | 1M | male |
| Michael Alexander Smith | Chief Legal Officer & Corporate Secretary | 1M | male |
| Sara Bonstein | Chief Financial Officer | 1M | female |
| S. Nicole Schaeffer | Chief People Strategy Officer | 660.8K | female |
| Eugene J. Sullivan FCCP | Chief Product Strategy Officer | 593.1K | — |
| Neil Hughes | GM & Head of Europe, Middle East and Africa | — | male |
| Bryan Dunn | Vice President of Investor Relations | — | — |
| Brian K. Kaspar | Chief Scientific Officer | — | male |
| Christie Camelio | Chief Compliance Officer | — | female |
| Claire Mulhearn | Vice President of Corporate Communications | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-10-03 | 2025-11-18 | Gilbert Cisneros | CA31 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-09-22 | 2025-10-10 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-08-08 | 2025-09-12 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-07-07 | 2025-08-15 | Gilbert Cisneros | CA31 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-06-16 | 2025-07-17 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-09 | 2025-05-14 | Josh Gottheimer | NJ05 | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2024-06-21 | 2024-07-09 | Josh Gottheimer | NJ05 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2024-05-28 | 2024-06-08 | Josh Gottheimer | NJ05 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2022-12-06 | 2023-01-13 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INSM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
